In a bid to expand its presence in breast cancer and small cell lung cancer, Puma Biotechnology has entered into a licensing agreement with Takeda. The deal, which is worth up to US$194.3 M, provides Puma with access to the aurora kinase A inhibitor alisertib, for the treatment of breast cancer and small cell lung cancer. Interestingly, in May 2015, Takeda discontinued the development of alisertib after it failed to meet its primary endpoint in a Phase III trial in relapsed and refractory peripheral T-cell lymphoma.